{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:54:45Z","timestamp":1787003685672,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-25752-4","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T10:33:18Z","timestamp":1763893998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab"],"prefix":"10.1038","volume":"15","author":[{"given":"Andrea","family":"Dalbeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Cattazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vicardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Campani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cabibbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Vivaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Pressiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Iavarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo A.","family":"Natola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Ponziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Svegliati-Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Sold\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Giuseppe","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Garajova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Celsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Bruccoleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sacerdoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tovoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ARTE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Ravaioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Boe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ascari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Bellucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Scorzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scandali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"issue":"6","key":"25752_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"25752_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0735-1097(99)00525-2","volume":"35","author":"CJ Vaughan","year":"2000","unstructured":"Vaughan, C. J., Gotto, A. M. & Basson, C. T. The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol. 35(1), 1\u201310. https:\/\/doi.org\/10.1016\/S0735-1097(99)00525-2 (2000).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"25752_CR3","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1158\/0008-5472.CAN-15-2613","volume":"76","author":"OF Kuzu","year":"2016","unstructured":"Kuzu, O. F., Noory, M. A. & Robertson, G. P. The role of cholesterol in cancer. Cancer Res. 76(8), 2063\u20132070. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2613 (2016).","journal-title":"Cancer Res."},{"issue":"10","key":"25752_CR4","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","volume":"15","author":"RG Kim","year":"2017","unstructured":"Kim, R. G., Loomba, R., Prokop, L. J. & Singh, S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 15(10), 1521-1530.e8. https:\/\/doi.org\/10.1016\/j.cgh.2017.04.039 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"17","key":"25752_CR5","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33(17), 1974\u20131982. https:\/\/doi.org\/10.1200\/JCO.2014.59.4358 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"25752_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron, T. et al. VEGF-A modulates expression of inhibitory checkpoints on CD8++ T cells in tumors. J. Exp. Med. 212(2), 139\u2013148. https:\/\/doi.org\/10.1084\/jem.20140559 (2015).","journal-title":"J. Exp. Med."},{"issue":"4","key":"25752_CR7","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng, A. L. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76(4), 862\u2013873. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030 (2022).","journal-title":"J. Hepatol."},{"key":"25752_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104110","author":"F Piscaglia","year":"2025","unstructured":"Piscaglia, F. et al. Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104110 (2025).","journal-title":"ESMO Open."},{"key":"25752_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae142","author":"MH Storandt","year":"2024","unstructured":"Storandt, M. H. et al. Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: A multi-institutional cohort study. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyae142 (2024).","journal-title":"Oncologist."},{"key":"25752_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1324140","author":"J Wang","year":"2024","unstructured":"Wang, J., Liu, C., Hu, R., Wu, L. & Li, C. Statin therapy: A potential adjuvant to immunotherapies in hepatocellular carcinoma. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1324140 (2024).","journal-title":"Front. Pharmacol."},{"key":"25752_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-024-05106-w","author":"WQ Shao","year":"2024","unstructured":"Shao, W. Q. et al. Cholesterol suppresses AMFR-mediated PDL1 ubiquitination and degradation in HCC. Mol. Cell. Biochem. https:\/\/doi.org\/10.1007\/s11010-024-05106-w (2024).","journal-title":"Mol. Cell. Biochem."},{"key":"25752_CR12","unstructured":"Cao, R., Zhang, S., Ma, D. & Hu L. Angiogenesis inhibition combined with bevacizumab for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Mol. Clin. Oncol. 241(7) (2017)."},{"issue":"3","key":"25752_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 76(3), 681\u2013693. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018 (2022).","journal-title":"J. Hepatol."},{"issue":"6","key":"25752_CR14","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79(6), 1542\u20131556. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003 (2023).","journal-title":"J. Hepatol."},{"issue":"2","key":"25752_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer. 45(2), 228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (2009).","journal-title":"Eur. J. Cancer."},{"key":"25752_CR16","unstructured":"R: The R Project for Statistical Computing. Available online: https:\/\/www.r- proje ct. org\/."},{"key":"25752_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"D Ho","year":"2011","unstructured":"Ho, D., Imai, K., King, G. & Stuart, E. A. MatchIt: Nonparametric preprocessing for parametric causal inference. J. Stat. Softw. 42, 1\u201328 (2011).","journal-title":"J. Stat. Softw."},{"key":"25752_CR18","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","volume":"69","author":"J Bosch","year":"2020","unstructured":"Bosch, J., Gracia-Sancho, J. & Abraldes, J. G. Cirrhosis as new indication for statins. Gut. 69, 953\u2013962 (2020).","journal-title":"Gut."},{"issue":"6","key":"25752_CR19","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1097\/HEP.0000000000000278","volume":"78","author":"S Sharpton","year":"2023","unstructured":"Sharpton, S. & Loomba, R. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. Hepatology 78(6), 1896\u20131906 (2023).","journal-title":"Hepatology"},{"issue":"10","key":"25752_CR20","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/liv.15656","volume":"43","author":"Wu Szu-Yuan","year":"2023","unstructured":"Szu-Yuan, Wu. et al. Protective effects of statins on the incidence of NAFLD\u2013related decompensated cirrhosis in T2DM. Liver Int. 43(10), 2232\u20132244 (2023).","journal-title":"Liver Int."},{"issue":"6","key":"25752_CR21","doi-asserted-by":"publisher","first-page":"E2320222","DOI":"10.1001\/jamanetworkopen.2023.20222","volume":"6","author":"MS Vell","year":"2023","unstructured":"Vell, M. S. et al. Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality. JAMA Netw. Open. 6(6), E2320222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.20222 (2023).","journal-title":"JAMA Netw. Open."},{"issue":"7","key":"25752_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/apt.14243","volume":"46","author":"UC Bang","year":"2017","unstructured":"Bang, U. C., Benfield, T. & Bendtsen, F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. Aliment. Pharmacol. Ther. 46(7), 673\u2013680 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"25752_CR23","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","volume":"156","author":"DE Kaplan","year":"2019","unstructured":"Kaplan, D. E. et al. Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. Gastroenterology 156(6), 1693-1706.e12. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.026 (2019).","journal-title":"Gastroenterology"},{"issue":"6","key":"25752_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/apt.12430","volume":"38","author":"C Motzkus-Feagans","year":"2013","unstructured":"Motzkus-Feagans, C., Pakyz, A. L., Ratliff, S. M., Bajaj, J. S. & Lapane, K. L. Statin use and infections in Veterans with cirrhosis. Aliment. Pharmacol. Ther. 38(6), 611\u2013618 (2013).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"25752_CR25","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.jhep.2021.12.034","volume":"76","author":"N Mahmud","year":"2022","unstructured":"Mahmud, N. et al. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. J. Hepatol. 76(5), 1100\u20131108. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.034 (2022).","journal-title":"J. Hepatol."},{"key":"25752_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000332","author":"TM Kronborg","year":"2023","unstructured":"Kronborg, T. M. et al. Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial. Hepatol. Commun. https:\/\/doi.org\/10.1097\/HC9.0000000000000332 (2023).","journal-title":"Hepatol. Commun."},{"key":"25752_CR27","doi-asserted-by":"crossref","unstructured":"Pose, E., Jim\u00e9nez, C., Zaccherini, G., et al. Simvastatin and rifaximin in decompensated cirrhosis: A randomized clinical trial. JAMA. Published online 2025.","DOI":"10.1001\/jama.2025.6144"},{"key":"25752_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000519","author":"Y Chen","year":"2024","unstructured":"Chen, Y. & Wong, C. C. L. The mechanistic insights behind the anticancer effects of statins in liver cancer. Hepatol. Commun. https:\/\/doi.org\/10.1097\/HC9.0000000000000519 (2024).","journal-title":"Hepatol. Commun."},{"key":"25752_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07796-7","author":"SY Yang","year":"2021","unstructured":"Yang, S. Y. et al. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-021-07796-7 (2021).","journal-title":"BMC Cancer."},{"key":"25752_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38110-4","author":"Y Cho","year":"2019","unstructured":"Cho, Y., Kim, M. S., Nam, C. M. & Kang, E. S. Statin use is associated with decreased hepatocellular carcinoma recurrence in liver transplant patients. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-018-38110-4 (2019).","journal-title":"Sci. Rep."},{"key":"25752_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020249","author":"JE Han","year":"2024","unstructured":"Han, J. E. et al. The impact of statins on the survival of patients with advanced hepatocellular carcinoma treated with sorafenib or lenvatinib. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16020249 (2024).","journal-title":"Cancers (Basel)."},{"issue":"3","key":"25752_CR32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2019.04.021","volume":"71","author":"JL Jouve","year":"2019","unstructured":"Jouve, J. L. et al. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. J. Hepatol. 71(3), 516\u2013522 (2019).","journal-title":"J. Hepatol."},{"key":"25752_CR33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12072-020-10120-3","volume":"15","author":"JF Blanc","year":"2021","unstructured":"Blanc, J. F. et al. Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis. Hepatol. Int. 15, 93\u2013104 (2021).","journal-title":"Hepatol. Int."},{"key":"25752_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70928-z","author":"M Rimini","year":"2024","unstructured":"Rimini, M. et al. Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-024-70928-z (2024).","journal-title":"Sci. Rep."},{"issue":"7854","key":"25752_CR35","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592(7854), 450\u2013456. https:\/\/doi.org\/10.1038\/s41586-021-03362-0 (2021).","journal-title":"Nature"},{"key":"25752_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2022.11.017","volume":"180","author":"A Casadei-Gardini","year":"2023","unstructured":"Casadei-Gardini, A. et al. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real-life worldwide population. Eur. J. Cancer. 180, 9\u201320. https:\/\/doi.org\/10.1016\/j.ejca.2022.11.017 (2023).","journal-title":"Eur. J. Cancer."},{"key":"25752_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100591","author":"M Rimini","year":"2022","unstructured":"Rimini, M. et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international propensity score matching analysis. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100591 (2022).","journal-title":"ESMO Open."},{"key":"25752_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000562","author":"T de Castro","year":"2024","unstructured":"de Castro, T. et al. Atezolizumab\/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort. Hepatol. Commun. https:\/\/doi.org\/10.1097\/HC9.0000000000000562 (2024).","journal-title":"Hepatol. Commun."},{"issue":"41","key":"25752_CR39","first-page":"111","volume":"2020","author":"F Mach","year":"2019","unstructured":"Mach, F. et al. ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020(41), 111\u2013188 (2019).","journal-title":"Eur. Heart J."},{"issue":"4","key":"25752_CR40","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","volume":"77","author":"K Staufer","year":"2022","unstructured":"Staufer, K. et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J. Hepatol. 77(4), 918\u2013930. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.040 (2022).","journal-title":"J. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25752-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25752-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25752-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:53:46Z","timestamp":1764082426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25752-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25752"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25752-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Giuseppe Cabibbo has served on in advisory board and received speaker fees for Bayer, Eisai, Ipsen, and AstraZeneca, MSD, Roche, Gilead. Ciro Celsa received speaker fees for AstraZeneca, EISAI, MSD, Ipsen,\u00a0and received grants from Roche. Andrea Dalbeni is a consultant for Roche,\u00a0Astrazeneca, Eisai, MSD. Support for congress attendance from Roche, Astrazeneca, Eisai, MSD. Massimo Iavarone in advisory board and received speaker fees for Gilead Sciences, Bayer, AstraZeneca, Roche, Roche Diagnostics, EISAI, IPSEN, MSD. Tiziana Pressiani received\/reports consulting fees from Bayer, Ipsen and Astra Zeneca; institutional research funding from Roche, Bayer, Astra Zeneca.; support for congress attendance from Roche. Lorenza Rimassa reports receiving grant \/ research funding from AbbVie, Agios, AstraZeneca, BeiGene, Eisai, Eli Lilly, Exelixis, Fibrogen, Incyte, IPSEN, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, TransThera Sciences and Zymeworks. Consulting fees from AbbVie, AstraZeneca, Basilea, Bayer, Bristol Myers Squibb, Eisai, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, IPSEN, IQVIA, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology and Zymeworks. Lecture fees from AstraZeneca, Bayer, Bristol Myers Squibb, Guerbet, Incyte, IPSEN, Roche and Servier. Travel expenses from Astra Zeneca. Francesca Romana Ponziani received speaker fees, advisory board fees and travel grants from Bayer, MSD, Roche, Eisai, Ipsen,\u00a0Astra-Zeneca, Gilead,\u00a0Abbvie. Caterina Sold\u00e0 reports consulting\/advisory role for MSD and EISAI; speakers\u2019 bureau for Roche and MSD. Francesco Tovoli is a consultant for Roche,\u00a0Astrazeneca, Eisai. Caterina Vivaldi CV reports consulting or advisory role for Amgen, AstraZeneca, BMS, EISAI, Incyte, MSD, Roche, Servier, Taiho Oncology. All the other authors do not report any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41844"}}